注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
DiaMedica Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于开发神经和肾脏疾病的治疗方法,例如急性缺血性中风(AIS)和慢性肾脏疾病(CKD)。该公司的主导产品DM199模仿天然存在的人类激肽释放酶-1(KLK1)蛋白的行为,以保持和恢复中风受损组织的循环并改善整体肾功能。KLK1是一种丝氨酸蛋白酶或蛋白质,主要在肾脏、胰腺和唾液腺中产生。DM199疗法有可能改善关键系统的循环和整体功能,以及减少炎症和氧化应激。该公司还拥有其他针对IgA肾病和患有CKD的非裔美国人的产品线。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
R. Michael Giuffre | 68 | 2010 | Independent Director |
Philip Bath | - | 2023 | Member of Stroke Advisory Board |
Richard D. Pilnik | 67 | 2009 | Independent Chairman |
Charles Herzog | - | - | Member of Kidney Scientific Advisory Board |
Aldo Peixoto | - | 2019 | Member of Kidney Scientific Advisory Board |
James T. Parsons | 59 | 2015 | Independent Director |
Dietrich John Pauls | 53 | 2005 | President, CEO & Director |
John Volpi | - | - | Member of Stroke Clinical Advisory Board |
Rajiv Agarwal | - | 2019 | Member of Kidney Scientific Advisory Board |
Glenn Matthew Chertow | - | 2019 | Member of Kidney Scientific Advisory Board |
Richard Edward Kuntz | 67 | 2023 | Independent Director |
Scott Eric Kasner | - | - | Member of Stroke Clinical Advisory Board |
George L. Bakris | - | 2019 | Member of Kidney Scientific Advisory Board |
Charles Pauling Semba | 63 | 2021 | Independent Director |
Tanya N. Lewis | 53 | 2023 | Independent Director |
Michael D. Hill | - | 2024 | Member of the Stroke Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核